Trial Profile
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 24 Jul 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Results published in the Blood
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition